Cite
HARVARD Citation
Scheurer, M. et al. (2022). Germline polymorphisms in MGMT associated with temozolomide-related myelotoxicity risk in patients with glioblastoma treated on NRG Oncology/RTOG 0825. Neuro-oncology advances. 4 (1), p. . [Online].